[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112013003257A2 - anticorpos egfr humanizados. - Google Patents

anticorpos egfr humanizados.

Info

Publication number
BR112013003257A2
BR112013003257A2 BR112013003257A BR112013003257A BR112013003257A2 BR 112013003257 A2 BR112013003257 A2 BR 112013003257A2 BR 112013003257 A BR112013003257 A BR 112013003257A BR 112013003257 A BR112013003257 A BR 112013003257A BR 112013003257 A2 BR112013003257 A2 BR 112013003257A2
Authority
BR
Brazil
Prior art keywords
egfr antibodies
humanized
humanized egfr
relates
present
Prior art date
Application number
BR112013003257A
Other languages
English (en)
Inventor
Antje Danielczyk
Steffen Goletz
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of BR112013003257A2 publication Critical patent/BR112013003257A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

anticorpos egfr humanizados. a presente invenção refere-se a anticorpos anti-egfr humanizados que tem propriedades de ligação de antígeno similares àquelas de anticorpos anti-egfr de murinos ou quiméricos dos quais são derivados. em particular, a presente invenção refere-se a anticorpos anti-egfr humanizados que são úteis no tratamento do câncer.
BR112013003257A 2010-08-10 2011-08-10 anticorpos egfr humanizados. BR112013003257A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37218610P 2010-08-10 2010-08-10
EP10008319 2010-08-10
EP2010004880 2010-08-10
PCT/EP2011/063781 WO2012020059A1 (en) 2010-08-10 2011-08-10 Humanized egfr antibodies

Publications (1)

Publication Number Publication Date
BR112013003257A2 true BR112013003257A2 (pt) 2016-06-14

Family

ID=44510957

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013003257A BR112013003257A2 (pt) 2010-08-10 2011-08-10 anticorpos egfr humanizados.

Country Status (4)

Country Link
EP (1) EP2603527A1 (pt)
CN (1) CN103025760A (pt)
BR (1) BR112013003257A2 (pt)
WO (1) WO2012020059A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014010750A (es) 2012-03-08 2015-02-05 Halozyme Inc Anticuerpos receptores del factor de crecimiento anti-epidermico condicionalmente activos y metodos de uso de los mismos.
JP6324381B2 (ja) 2012-07-31 2018-05-16 クラウン バイオサイエンス インコーポレイテッド（タイカン） 抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー
WO2014052713A2 (en) 2012-09-27 2014-04-03 Massachusetts Institute Of Technology Her2-and vegf-a-binding proteins with enhanced stability
EA201591977A1 (ru) * 2013-04-22 2016-06-30 Гликотоп Гмбх Противораковая терапия анти-egfr антителами, имеющими низкое фукозилирование
MX2016003256A (es) 2013-09-12 2016-06-07 Halozyme Inc Anticuerpos modificados del receptor de factor de crecimiento anti-epidermico y metodos de uso de los mismos.
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
WO2017205465A2 (en) 2016-05-24 2017-11-30 Griswold Karl Edwin Antibodies and methods of making same
CN112300278A (zh) * 2019-07-25 2021-02-02 上海交通大学 抗人egfr嵌合抗体及其制备方法和用途
CN111171151B (zh) * 2019-12-26 2021-09-14 佛山汉腾生物科技有限公司 抗egfr纳米抗体及其应用
KR20240154641A (ko) 2022-03-02 2024-10-25 바이오뮤넥스 파마슈티컬스 Her-3, 및 her-2 또는 egfr에 결합하는 이중특이적 항체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EA017622B1 (ru) 2006-09-10 2013-01-30 Гликотоп Гмбх Полностью человеческая высокопродуктивная система получения усовершенствованных антител и белков

Also Published As

Publication number Publication date
CN103025760A (zh) 2013-04-03
EP2603527A1 (en) 2013-06-19
WO2012020059A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
BR112013003257A2 (pt) anticorpos egfr humanizados.
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12017500890A1 (en) Antibody drug conjugates
WO2012078688A3 (en) Humanized antibodies to liv-1 and use of same to treat cancer
PH12016501384B1 (en) Human antibodies to pd-l1
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
WO2012058588A3 (en) Novel egfr-binding molecules and immunoconjugates thereof
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
NZ702748A (en) Cd33 antibodies and use of same to treat cancer
WO2013164689A3 (en) Humanized pan-her antibody compositions
PH12016501366A1 (en) Novel anti-baff antibodies
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
NZ611785A (en) Anti-notch1 antibodies
JO3437B1 (ar) أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
PH12015501360A1 (en) Bmp-6 antibodies
NZ724395A (en) Anti-pdgf-c antibodies
MX2018011244A (es) Anticuerpos monoclonales neutralizantes para il-25 y usos de estos.
WO2013071127A8 (en) Monoclonal antibodies against serotransferrin antigens, and uses therefor
NZ768582A (en) Antibodies and uses thereof to detect folate receptor 1

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired